As global markets navigate a landscape marked by heightened inflation concerns and geopolitical tensions, major indices like the Dow Jones Industrial Average and S&P 500 have reached new heights, driven in part by enthusiasm for AI-related stocks. Amid this complex environment, small-cap and value stocks have shown resilience, outperforming their larger counterparts.In such a setting, identifying undervalued stocks becomes crucial for investors looking to capitalize on potential market inefficiencies. By focusing on companies that may be trading below their fair value estimates, investors can potentially uncover opportunities that align with current economic trends and market dynamics.
Top 10 Undervalued Stocks Based On Cash Flows
| Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|---|---|---|---|
| XTPL (WSE:XTP) |
PLN59.70 |
PLN118.97 |
49.8% |
| Sansan (TSE:4443) |
¥1539.00 |
¥3068.75 |
49.8% |
| NCC (OM:NCC B) |
SEK200.60 |
SEK398.26 |
49.6% |
| Holcim (SWX:HOLN) |
CHF73.84 |
CHF146.72 |
49.7% |
| GMO internet group (TSE:9449) |
¥3430.00 |
¥6813.46 |
49.7% |
| freee K.K (TSE:4478) |
¥2179.00 |
¥4335.91 |
49.7% |
| Fagerhult Group (OM:FAG) |
SEK19.72 |
SEK39.23 |
49.7% |
| Cint Group (OM:CINT) |
SEK5.74 |
SEK11.46 |
49.9% |
| B&S Group (ENXTAM:BSGR) |
€5.85 |
€11.66 |
49.8% |
| APR (KOSE:A278470) |
₩388500.00 |
₩772855.46 |
49.7% |
Let's dive into some prime choices out of the screener.
Laboratorios Farmaceuticos Rovi
Overview:Laboratorios Farmaceuticos Rovi, S.A. is engaged in the manufacturing, selling, and marketing of pharmaceutical products across Spain, the European Union, OECD countries, and internationally with a market cap of €3.07 billion.
Operations:The company's revenue segments include the production and distribution of pharmaceutical products within Spain, the European Union, OECD countries, and globally.
Estimated Discount To Fair Value:41.4%
Laboratorios Farmaceuticos Rovi is trading at €60.1, significantly below its estimated future cash flow value of €102.52, suggesting undervaluation. Although recent earnings showed a decline in net income to €9.48 million from €18.1 million the previous year, analysts forecast robust annual profit growth of 16.4%, outpacing the Spanish market's average growth rate. Despite short-term volatility and lowered revenue guidance for 2026, long-term cash flow projections remain favorable.
Hyundai Rotem
Overview:Hyundai Rotem Company manufactures and sells railway vehicles, defense systems, and plants and machinery in South Korea and internationally, with a market cap of ₩22.48 trillion.
Operations:The company's revenue segments are composed of ₩2.23 trillion from the Railway Sector, ₩3.36 trillion from the Defense Industry, and ₩528.80 million from Eco Plant operations.
Estimated Discount To Fair Value:48.4%
Hyundai Rotem is trading at ₩213,000, significantly below its estimated future cash flow value of ₩412,685.5, indicating potential undervaluation. Recent earnings for Q1 2026 showed sales growth to ₩1.46 trillion from ₩1.18 trillion a year ago and net income increased to ₩202.7 billion from ₩157.1 billion. Earnings are expected to grow significantly over the next three years despite revenue growth trailing the market average slightly at 18.4% annually compared to 16.5%.
Sansan
Overview:Sansan, Inc. is a Japanese company that plans, develops, and sells cloud-based solutions with a market capitalization of ¥193.50 billion.
Operations:The company's revenue segments include the Sansan/Bill One Business, generating ¥44.70 billion, and the Eight Business, contributing ¥6.38 billion.
Estimated Discount To Fair Value:49.8%
Sansan is trading at ¥1,539, significantly below its estimated future cash flow value of ¥3,068.75. Earnings grew 31.5% last year and are forecast to grow 34.99% annually, outpacing the Japanese market's 8.9%. The company announced a share buyback program worth ¥2 billion to enhance shareholder returns and improve capital efficiency. Recent earnings for nine months showed sales at ¥39.27 billion compared to ¥31.14 billion previously, with net income rising substantially to ¥4.11 billion from ¥1.70 billion.
Seize The Opportunity
-
Access the full spectrum of 400 Undervalued Global Stocks Based On Cash Flows by clicking on this link.
-
Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St , where you can monitor all the vital signs of your stocks effortlessly.
-
Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Looking For Alternative Opportunities?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BME:ROVI KOSE:A064350 and TSE:4443.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
